Schroders3h
IBT's financial year in review
A year of recovery After a challenging period, 2024 has seen a more positive backdrop emerge for the biotechnology sector. In ...
McKnight's Long-Term Care News3h
Schizophrenia treatment offers alternative with fewer side effects
The Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), making it the first major ...
mindsitenews19h
Will a New Schizophrenia Drug Improve Peoples’ Lives?
The FDA approved a new drug for schizophrenia. Discrimination is stressing Chinese Americans and damaging their mental health.
Pharmaceutical Technology20h
FDA approves PureTech’s KarXT to treat schizophrenia in adults
PureTech Health has obtained approval from the US Food and Drug Administration (FDA) for KarXT to treat schizophrenia in ...